Clinical trials: Wasting Syndrome

Muscle Wasting (Atrophy) After Hip Fracture Surgery

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

• Completed
• Age: 60 years and older
• Phase 2
• Results posted

The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.

Trial name

NCT02152761

Testing

bimagrumab

Where

53 sites in United States, Argentina and 17 more

Volunteers

251 people

Sponsor

Novartis Pharmaceuticals